The following factors are associated with prognosis in ALL patients:
age at diagnosis is considered to be a strong prognostic factor. According to a study carried out at children’s Research Hospital with 847 children with ALL:
children between the age 1 to 9 had a better outcome than infants or adolescents. The 5 year event free survival estimates were (1)
for children aged 1-9 - 88%
adolescents aged 10–15 years - 73%
older than 15 years - 69%
babies younger than 12 months - 44%
prognosis was poor especially for babies younger than 6 months
age-specific mortality rates rise steadily from birth and more steeply from around age 45-49. The highest rates are in the 85 to 89 age group for males and the 90+ age group for females (2)
increased leukocyte count presents with poor prognostic outcome.
this is especially true in patients with B-cell precursor disease
in T cell ALL, a count of more than 100x109/L is associated with an increased risk of relapse in the CNS
high risk of early complications are seen in patients with extreme hyperleucocytosis (>400x109/L) e.g - CNS haemorrhage and pulmonary and neurological events due to leucostasis (1)
chromosomal abnormality
poorer outcome is also associated with Philadelphia chromosome, t(4;11) with MLL-AF4 fusion, and hypodiploidy (<44 chromosomes per leukaemic cell)
favourable prognosis was seen in patients with hyperdiploidy (>50 chromosomes), TEL-AML1fusion, and trisomy 4, 10, and 17
Children respond well to treatment:
95% achieve complete remission
50-60% of whom are cured with postremission chemotherapy
Fewer advances have been achieved in adults:
80% achieve complete remission
about 35% achieve long-term disease-free survival
The poorer response seen in adults may reflect undertreatment because of the increased risk of drug toxicity.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page